Diclofénac ratiopharm

Diclofénac ratiopharm may be available in the countries listed below.

Ingredient matches for Diclofénac ratiopharm

Diclofenac

Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Diclofénac ratiopharm in the following countries:

• France

International Drug Name Search

Lanvis

Lanvis may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

UK matches:

• Lanvis Tablets (SPC)

Ingredient matches for Lanvis

Tioguanine

Tioguanine is reported as an ingredient of Lanvis in the following countries:

• Argentina


• Australia


• Bahrain


• Belgium


• Brazil


• Canada


• Chile


• Czech Republic


• Egypt


• Estonia


• France


• Guyana


• Hong Kong


• Iran


• Iraq


• Ireland


• Israel


• Jordan


• Kuwait


• Latvia


• Lebanon


• Lithuania


• Netherlands


• New Zealand


• Oman


• Poland


• Qatar


• Romania


• Saudi Arabia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Sweden


• Switzerland


• Syria


• Taiwan


• Thailand


• Turkey


• United Arab Emirates


• United Kingdom


• Yemen

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Atenolol AbZ

Atenolol AbZ may be available in the countries listed below.

Ingredient matches for Atenolol AbZ

Atenolol

Atenolol is reported as an ingredient of Atenolol AbZ in the following countries:

• Germany

International Drug Name Search

Ozurdex

Ozurdex is a brand name of dexamethasone ophthalmic, approved by the FDA in the following formulation(s):

OZURDEX (dexamethasone - implant; intravitreal)

• 
  Manufacturer: ALLERGAN
  
  Approval date: June 17, 2009
  
  Strength(s): 0.7MG ^[RLD]

Has a generic version of Ozurdex been approved?

No. There is currently no therapeutically equivalent version of Ozurdex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ozurdex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods for treating inflammation-mediated conditions of the eye
  Patent 6,726,918
  Issued: April 27, 2004
  Inventor(s): Vernon G.; Wong & Mae W. L.; Hu
  Assignee(s): Oculex Pharmaceuticals, Inc.
  Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 &mgr;g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 &mgr;g/ml dexamethasone for at least about three weeks.
  
  Patent expiration dates:
  
  
  • October 20, 2020
    
    ✓ 
    Patent use: TREATMENT OF MACULAR EDEMA
    ✓ 
    Drug product
  
  
  
  • October 20, 2020
    
    ✓ 
    Patent use: TREATMENT OF UVEITIS
    ✓ 
    Drug product
  
  



• 
  Methods and apparatus for delivery of ocular implants
  Patent 6,899,717
  Issued: May 31, 2005
  Inventor(s): Weber; David & Kane; Ingrid & Rehal; Mike & Lathrop, III; Robert L. & Aptekarev; Kenny
  Assignee(s): Allergan, Inc.
  An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
  
  Patent expiration dates:
  
  
  • November 1, 2023
    
    ✓ 
    Patent use: DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
  
  



• 
  Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
  Patent 7,033,605
  Issued: April 25, 2006
  Inventor(s): Wong; Vernon G.
  Assignee(s): Allergan, Inc.
  Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  
  Patent expiration dates:
  
  
  • October 20, 2020
    
    ✓ 
    Drug product
  
  



• 
  Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
  Patent 7,767,223
  Issued: August 3, 2010
  Inventor(s): Wong; Vernon G.
  Assignee(s): Allergan, Inc.
  Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  
  Patent expiration dates:
  
  
  • November 28, 2021
    
    ✓ 
    Drug product
  
  



• 
  Ocular implant made by a double extrusion process
  Patent 8,034,366
  Issued: October 11, 2011
  Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
  Assignee(s): Allergan, Inc.
  The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
  
  Patent expiration dates:
  
  
  • January 9, 2023
    
    ✓ 
    Patent use: TREATMENT OF UVEITIS
    ✓ 
    Drug product
  
  
  
  • January 9, 2023
    
    ✓ 
    Patent use: TREATMENT OF MACULAR EDEMA
    ✓ 
    Drug product
  
  



• 
  Ocular implant made by a double extrusion process
  Patent 8,034,370
  Issued: October 11, 2011
  Inventor(s): Shiah; Jane-Guo & Bhagat; Rahul & Blanda; Wendy M. & Nivaggioli; Thierry & Peng; Lin & Chou; David & Weber; David A.
  Assignee(s): Allergan, Inc.
  The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
  
  Patent expiration dates:
  
  
  • January 9, 2023
    
    ✓ 
    Drug product
  
  



• 
  Methods for reducing edema
  Patent 8,043,628
  Issued: October 25, 2011
  Inventor(s): Wong; Vernon G.
  Assignee(s): Allergan, Inc.
  Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  
  Patent expiration dates:
  
  
  • October 20, 2020
    
    ✓ 
    Patent use: TREATMENT OF MACULAR EDEMA
    ✓ 
    Drug product
  
  



• 
  Implants and methods for treating inflammation-mediated conditions of the eye
  Patent 8,063,031
  Issued: November 22, 2011
  Inventor(s): Wong; Vernon G. & Hu; Mae W. L.
  Assignee(s): Allergan, Inc.
  Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
  
  Patent expiration dates:
  
  
  • October 20, 2020
    
    ✓ 
    Drug product
  
  



• 
  Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
  Patent 8,088,407
  Issued: January 3, 2012
  Inventor(s): Wong; Vernon G
  Assignee(s): Allergan, Inc.
  Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  
  Patent expiration dates:
  
  
  • October 20, 2020
    
    ✓ 
    Patent use: TREATMENT OF MACULAR EDEMA
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 17, 2012 - NEW DOSAGE FORM
  
  
  • September 24, 2017 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Ozurdex Consumer Information (Drugs.com)
• Ozurdex Consumer Information (Cerner Multum)
• Ozurdex Advanced Consumer Information (Micromedex)
• Dexamethasone Drops Consumer Information (Wolters Kluwer)
• Dexamethasone Suspension Consumer Information (Wolters Kluwer)
• Dexamethasone intravitreal implant Consumer Information (Cerner Multum)
• Dexamethasone ophthalmic Consumer Information (Cerner Multum)
• Dexamethasone Intraocular Advanced Consumer Information (Micromedex)

Hyabak

Hyabak may be available in the countries listed below.

Ingredient matches for Hyabak

Hyaluronic Acid

Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Hyabak in the following countries:

• Germany


• Portugal

International Drug Name Search

Dopadura B

Dopadura B may be available in the countries listed below.

Ingredient matches for Dopadura B

Benserazide

Benserazide hydrochloride (a derivative of Benserazide) is reported as an ingredient of Dopadura B in the following countries:

• Germany

Levodopa

Levodopa is reported as an ingredient of Dopadura B in the following countries:

• Germany

International Drug Name Search

Weidos

Weidos may be available in the countries listed below.

Ingredient matches for Weidos

Ranitidine

Ranitidine is reported as an ingredient of Weidos in the following countries:

• Taiwan

International Drug Name Search

Alfuzosine Mylan L.P.

Alfuzosine Mylan L.P. may be available in the countries listed below.

Ingredient matches for Alfuzosine Mylan L.P.

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Alfuzosine Mylan L.P. in the following countries:

• France

International Drug Name Search

Grisenova

Grisenova may be available in the countries listed below.

Ingredient matches for Grisenova

Griseofulvin

Griseofulvin is reported as an ingredient of Grisenova in the following countries:

• Greece

International Drug Name Search

Progestin

Progestin may be available in the countries listed below.

Ingredient matches for Progestin

Progesterone

Progesterone is reported as an ingredient of Progestin in the following countries:

• El Salvador


• Guatemala


• Nicaragua


• Panama

International Drug Name Search

Calcicar

Calcicar may be available in the countries listed below.

Ingredient matches for Calcicar

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Calcicar in the following countries:

• Bangladesh

International Drug Name Search

Desferin

Desferin may be available in the countries listed below.

Ingredient matches for Desferin

Deferoxamine

Deferoxamine mesilate (a derivative of Deferoxamine) is reported as an ingredient of Desferin in the following countries:

• Spain

International Drug Name Search

Capoten

In the US, Capoten (captopril systemic) is a member of the drug class angiotensin converting enzyme inhibitors and is used to treat Cystinuria, Diabetic Kidney Disease, Heart Failure, High Blood Pressure, Hypertensive Emergency and Left Ventricular Dysfunction.

US matches:

• Capoten

UK matches:

• Capoten 12.5 mg Tablets (SPC)
• Capoten Tablets 12.5mg, 25mg, 50mg (SPC)
• CAPOTEN TABLETS 25 mg & 50 mg (SPC)

Ingredient matches for Capoten

Captopril

Captopril is reported as an ingredient of Capoten in the following countries:

• Australia


• Bahrain


• Belgium


• Brazil


• Canada


• Chile


• China


• Colombia


• Czech Republic


• Denmark


• Ethiopia


• Georgia


• Greece


• Hong Kong


• Iceland


• Indonesia


• Ireland


• Italy


• Kenya


• Luxembourg


• New Zealand


• Norway


• Oman


• Peru


• Philippines


• Portugal


• Russian Federation


• Singapore


• Spain


• Taiwan


• Tanzania


• Thailand


• Uganda


• United Kingdom


• United States


• Venezuela

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Céfépime

Céfépime may be available in the countries listed below.

Ingredient matches for Céfépime

Cefepime

Céfépime (DCF) is known as Cefepime in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Plaquenil

In the US, Plaquenil (hydroxychloroquine systemic) is a member of the following drug classes: antimalarial quinolines, antirheumatics and is used to treat Dermatomyositis, Malaria, Malaria Prevention, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus and Undifferentiated Connective Tissue Disease.

US matches:

• Plaquenil


• Plaquenil Sulfate

UK matches:

• Plaquenil
• Plaquenil Tablets (SPC)

Ingredient matches for Plaquenil

Hydroxychloroquine

Hydroxychloroquine is reported as an ingredient of Plaquenil in the following countries:

• Tunisia

Hydroxychloroquine sulfate (a derivative of Hydroxychloroquine) is reported as an ingredient of Plaquenil in the following countries:

• Argentina


• Australia


• Belgium


• Canada


• Czech Republic


• Denmark


• Estonia


• France


• Georgia


• Ghana


• Hong Kong


• Iceland


• Ireland


• Israel


• Italy


• Kenya


• Latvia


• Lithuania


• Luxembourg


• Malaysia


• Malta


• Mexico


• Netherlands


• New Zealand


• Nigeria


• Norway


• Romania


• Singapore


• Slovakia


• Sweden


• Switzerland


• Taiwan


• Tanzania


• Thailand


• Uganda


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.